MYGN » Topics » EXHIBIT INDEX

This excerpt taken from the MYGN 8-K filed Nov 6, 2009.

EXHIBIT INDEX

 

Exhibit

Number

  

Description

10.1

   Myriad Genetics, Inc. 2003 Employee, Director and Consultant Stock Option Plan, as amended.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Nov 3, 2009.

EXHIBIT INDEX

 

Exhibit
Number

 

Description

99.1   Earnings release dated November 3, 2009 for the three months ended September 30, 2009.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Aug 25, 2009.

EXHIBIT INDEX

 

Exhibit

Number

  

Description

99.1    Earnings release dated August 25, 2009 for the three and twelve months ended June 30, 2009.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Jul 7, 2009.

EXHIBIT INDEX

 

Exhibit
Number

 

Description

2.1   Separation and Distribution Agreement, dated June 30, 2009, by and between Myriad Genetics, Inc. and Myriad Pharmaceuticals, Inc.
10.1   Tax Sharing Agreement, dated June 30, 2009, by and between Myriad Genetics, Inc. and Myriad Pharmaceuticals, Inc.
10.2   Sublease Agreement, effective July 1, 2009, by and between Myriad Genetics, Inc. and Myriad Pharmaceuticals, Inc.
10.3   Employee Matters Agreement, dated June 30, 2009, by and between Myriad Genetics, Inc. and Myriad Pharmaceuticals, Inc.
99.1   Myriad Genetics, Inc. Unaudited Pro Forma Condensed Consolidated Financial Information.
99.2   Press release issued on June 30, 2009.
99.3   Press release issued on July 1, 2009.
This excerpt taken from the MYGN 8-K filed May 4, 2009.

EXHIBIT INDEX

 

Exhibit
Number

  

Description

99.1    Earnings release dated May 4, 2009 for the three and nine months ended March 31, 2009.

 

Page 4 of 4 Pages

This excerpt taken from the MYGN 8-K filed Apr 29, 2009.

EXHIBIT INDEX

 

Exhibit
Number

  

Description

99.1    Press release dated April 27, 2009.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Apr 13, 2009.

EXHIBIT INDEX

 

Exhibit
Number

  

Description

99.1    Press release dated April 08, 2009.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Feb 3, 2009.

EXHIBIT INDEX

 

Exhibit
Number

  

Description

99.1    Earnings release dated February 3, 2009 for the three and six months ended December 31, 2008.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Jan 22, 2009.

EXHIBIT INDEX

 

Exhibit
Number

  

Description

99.1    Press release dated January 21, 2009.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Dec 23, 2008.

EXHIBIT INDEX

 

Exhibit
Number

  

Description

99.1    Press release dated December 22, 2008.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Nov 19, 2008.

EXHIBIT INDEX

 

Exhibit
Number

  

Description

  3.1    Certificate of Amendment of Restated Certificate of Incorporation of Myriad Genetics, Inc. as filed with the Secretary of State of the State of Delaware on November 14, 2008.
10.1    Myriad Genetics, Inc. 2003 Employee, Director and Consultant Stock Option Plan, as amended.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Nov 4, 2008.

EXHIBIT INDEX

 

Exhibit
Number

  

Description

99.1    Earnings release dated November 4, 2008 for the three months ended September 30, 2008.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Sep 12, 2008.

EXHIBIT INDEX

 

Exhibit
Number

  

Description

99.1    Press release dated September 11, 2008.

 

Page 4 of 4

These excerpts taken from the MYGN 10-K filed Aug 28, 2008.

EXHIBIT INDEX

 

Exhibit
Number

 

Description of Exhibits

(10.31)$   Summary of compensation arrangements applicable to the Registrant’s Named Executive Officers (FY 2008 Bonus and FY 2009 Salary)
(10.32)   Lease Agreement, dated March 11, 2008 between the Registrant and Boyer Research Park Associates IX, by it general partner, The Boyer Company, L.C.
(10.33)#   Co-marketing Agreement, dated May 21, 2008 between the Registrant and H. Lundbeck A/S
(21.1)   List of Subsidiaries of the Registrant
(23.1)   Consent of Independent Registered Public Accounting Firm (KPMG LLP)
(23.2)   Consent of Independent Registered Public Accounting Firm (Ernst & Young LLP)
(31.1)   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
(31.2)   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
(32)   Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

# Confidential treatment has been requested from the Commission as to certain portions.
$ Management contract or compensatory plan or arrangement.


Table of Contents

EXHIBIT INDEX

 








































































Exhibit
Number

 

Description of Exhibits

(10.31)$ Summary of compensation arrangements applicable to the Registrant’s Named Executive Officers (FY 2008 Bonus and FY 2009 Salary)
(10.32) Lease Agreement, dated March 11, 2008 between the Registrant and Boyer Research Park Associates IX, by it general partner, The Boyer Company, L.C.
(10.33)# Co-marketing Agreement, dated May 21, 2008 between the Registrant and H. Lundbeck A/S
(21.1) List of Subsidiaries of the Registrant
(23.1) Consent of Independent Registered Public Accounting Firm (KPMG LLP)
(23.2) Consent of Independent Registered Public Accounting Firm (Ernst & Young LLP)
(31.1) Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
(31.2) Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
(32) Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 





#Confidential treatment has been requested from the Commission as to certain portions.




$Management contract or compensatory plan or arrangement.





Table of Contents


This excerpt taken from the MYGN 8-K filed Aug 19, 2008.

EXHIBIT INDEX

 

Exhibit
Number

 

Description

99.1   Earnings release dated August 19, 2008 for the three and twelve months ended June 30, 2008.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed May 27, 2008.

EXHIBIT INDEX

 

Exhibit
Number

  

Description

99.1    The Registrant’s press release dated May 22, 2008.

 

4

This excerpt taken from the MYGN 8-K filed May 6, 2008.

EXHIBIT INDEX

 

Exhibit
Number

  

Description

99.1    Earnings release dated May 6, 2008 for the three and nine months ended March 31, 2008.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Feb 5, 2008.

EXHIBIT INDEX

 

Exhibit
Number

  

Description

99.1    Earnings release dated February 5, 2008 for the three and six months ended December 31, 2007.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Dec 5, 2007.

EXHIBIT INDEX

 

Exhibit
Number
  

Description

99.1    The Registrant’s press release dated December 4, 2007 concerning the submission of an Investigational New Drug (IND) application to the United States Food and Drug Administration to begin human clinical trials with its drug candidate, Vivecon, for the treatment of AIDS.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Nov 16, 2007.

EXHIBIT INDEX

 

Exhibit
Number
  

Description

  3.1    Myriad Genetics, Inc. Restated Bylaws.
99.1    Myriad Genetics, Inc. 2003 Employee, Directors and Consultant Stock Option Plan, as amended.

 

Page 5 of 5 Pages

This excerpt taken from the MYGN 8-K filed Nov 6, 2007.

EXHIBIT INDEX

 

Exhibit

Number

  

Description

  
10.1    Employment Agreement between Myriad Genetics, Inc. and Mr. James S. Evans dated March 3, 1995.
10.2    Resignation Agreement between Myriad Genetics, Inc. and Mr. Jay M. Moyes.

 

Page 5 of 5 pages

This excerpt taken from the MYGN 8-K filed Nov 1, 2007.

EXHIBIT INDEX

 

Exhibit

Number

 

Description

99.1   Earnings release dated November 1, 2007 for the three months ended September 30, 2007.
This excerpt taken from the MYGN 10-K filed Aug 29, 2007.

EXHIBIT INDEX

 

Exhibit
Number
  

Description of Exhibits

(10.25)    Summary of compensation arrangements applicable to the Registrant’s Named Executive Officers (FY 2007 Bonus and FY 2008 Salary)
(21.1)    List of Subsidiaries of the Registrant
(23.1)    Consent of Independent Registered Public Accounting Firm (KPMG LLP)
(23.2)    Consent of Independent Registered Public Accounting Firm (Ernst & Young LLP)
(31.1)    Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
(31.2)    Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   (32)    Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
This excerpt taken from the MYGN 8-K filed Aug 21, 2007.

EXHIBIT INDEX

 

Exhibit

Number

  

Description

99.1    Earnings release dated August 21, 2007 for the three and twelve months ended June 30, 2007.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed May 1, 2007.

EXHIBIT INDEX

 

Exhibit
Number
 

Description

99.1   Earnings release dated May 1, 2007 for the three and nine months ended March 31, 2007.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Feb 9, 2007.

EXHIBIT INDEX

 

Exhibit
Number
 

Description

1.1   Underwriting Agreement, dated February 8, 2007.
5.1   Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. regarding the validity of the common stock being offered.
23.1   Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1).
99.1   Press Release dated February 7, 2007.
99.2   Press Release dated February 8, 2007.
This excerpt taken from the MYGN 8-K filed Feb 6, 2007.

EXHIBIT INDEX

 

Exhibit
Number
  

Description

99.1    Earnings release dated February 6, 2007 for the three and six months ended December 31, 2006.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Feb 6, 2007.

EXHIBIT INDEX

 

Exhibit
Number
  

Description    

99.1    Earnings release dated February 6, 2007 for the three and six months ended December 31, 2006.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Nov 20, 2006.

EXHIBIT INDEX

 

Exhibit
Number
  

Description

99.1    Myriad Genetics, Inc. 2003 Employee, Directors and Consultant Stock Option Plan, as amended.
99.2    Myriad Genetics, Inc. Employee Stock Purchase Plan, as amended.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Nov 7, 2006.

EXHIBIT INDEX

 

Exhibit
Number
  

Description

99.1    Earnings release dated November 7, 2006 for the three months ended September 30, 2006.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Sep 14, 2006.

EXHIBIT INDEX

 

Exhibit
Number
  

Description

16.1    Letter from KPMG LLP dated September 14, 2006.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 10-K filed Sep 7, 2006.

EXHIBIT INDEX

 

Exhibit
Number
 

Description of Exhibits

(21.1)   List of Subsidiaries of the Registrant
(23.1)   Consent of KPMG LLP
(31.1)   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
(31.2)   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
(32)   Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
This excerpt taken from the MYGN 8-K filed Aug 22, 2006.

EXHIBIT INDEX

 

Exhibit
Number
  

Description

99.1    Earnings release dated August 22, 2006 for the three and twelve months ended June 30, 2006.
99.2    The Registrant’s press release dated August 22, 2006 concerning the completed enrollment of U.S. Phase 3 clinical trial of Flurizan.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Jun 21, 2006.

EXHIBIT INDEX

 

Exhibit

Number

  

Description

10.1    Fiscal year 2006 base salaries and bonuses and fiscal year 2007 base salaries for Myriad’s named executive officers.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed May 2, 2006.

EXHIBIT INDEX

 

Exhibit

Number

  

Description

99.1    Earnings release dated May 2, 2006 for the three and nine months ended March 31, 2006.
99.2    The Registrant’s press release dated May 2, 2006 concerning MPC-0920.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Mar 13, 2006.

EXHIBIT INDEX

 

Exhibit
Number
  

Description

99.1    The Registrant’s press release dated March 12, 2006.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Feb 7, 2006.

EXHIBIT INDEX

 

Exhibit
Number


  

Description


99.1    Earnings release dated February 7, 2006 for the three and six months ended December 31, 2005.

 

Pages 4 of 4 Pages

This excerpt taken from the MYGN 8-K filed Jan 9, 2006.

EXHIBIT INDEX

 

Exhibit
Number


  

Description


10.1    Myriad Genetics, Inc. 2003 Employee, Directors and Consultant Stock Option Plan, as amended.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Nov 9, 2005.

EXHIBIT INDEX

 

Exhibit

Number


  

Description


99.1    Press Release, dated November 8, 2005
This excerpt taken from the MYGN 8-K filed Nov 4, 2005.

EXHIBIT INDEX

 

Exhibit
Number


  

Description


1.1    Underwriting Agreement, dated November 3, 2005.
5.1    Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. regarding the validity of the common stock being offered.
23.1    Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1)
99.1    Press Release, dated November 3, 2005

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Oct 28, 2005.

EXHIBIT INDEX

 

 

Exhibit

Number


  

Description


99.1    Press Release dated October 28, 2005.

 

25

This excerpt taken from the MYGN 8-K filed Oct 26, 2005.

EXHIBIT INDEX

 

Exhibit
Number


  

Description


99.1    Earnings release dated October 26, 2005 for the three months ended September 30, 2005.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 10-K filed Sep 9, 2005.

EXHIBIT INDEX

 

Exhibit
Number


  

Description of Exhibits


(21.1)    List of Subsidiaries of the Registrant
(23.1)    Consent of KPMG LLP
(31.1)    Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
(31.2)    Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
(32)    Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002


This excerpt taken from the MYGN 8-K filed Aug 23, 2005.

EXHIBIT INDEX

 

Exhibit
Number


  

Description


99.1    Earnings release dated August 23, 2005 for the three and twelve months ended June 30, 2005.

 

Page 4 of 4 pages

This excerpt taken from the MYGN 8-K filed Jul 5, 2005.

EXHIBIT INDEX

 

Exhibit
Number


 

Description


99.1   Lease Agreement, effective as of May 31, 2005, between Myriad Genetics, Inc. and Boyer Research Park Associates VIII, by its general partner, The Boyer Company, L.C.
99.2   Letter of Understanding regarding Lease Agreement: Research Park – Phase IV.

 

Page 4 of 4 pages

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki